Vera Therapeutics, Inc. Interest Expense Nonoperating
Vera Therapeutics, Inc. (VERA) reported Interest Expense Nonoperating of $1.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-10
- Vera Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $1.85M, a 1.39% decline year-over-year.
- Vera Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $1.82M, a 1.73% increase year-over-year.
- Vera Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $1.90M, a 1.76% increase year-over-year.
- Vera Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $1.96M, a 1.24% increase year-over-year.
- Vera Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $7.53M, a 1.25% decline from fiscal 2024.
- Vera Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $7.63M, a 101.43% increase from fiscal 2023.
- Vera Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $3.79M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.85M 10-Q · filed 2026-08-10 | $3.67M 10-Q · filed 2026-08-10 | $5.58M derived: sum of 3 quarters · filed 2026-08-10 | $7.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.82M 10-Q · filed 2026-05-07 | $3.73M derived: sum of 2 quarters · filed 2026-05-07 | $5.69M derived: sum of 3 quarters · filed 2026-05-07 | $7.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.86M derived: sum of 2 quarters · filed 2026-02-26 | $5.74M derived: sum of 3 quarters · filed 2026-08-10 | $7.53M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.96M 10-Q · filed 2025-11-05 | $3.83M derived: sum of 2 quarters · filed 2026-08-10 | $5.63M 10-Q · filed 2025-11-05 | $7.50M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.87M 10-Q · filed 2026-08-10 | $3.67M 10-Q · filed 2026-08-10 | $5.54M derived: sum of 3 quarters · filed 2026-08-10 | $7.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.79M 10-Q · filed 2026-05-07 | $3.66M derived: sum of 2 quarters · filed 2026-05-07 | $5.60M derived: sum of 3 quarters · filed 2026-05-07 | $7.51M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.81M derived: sum of 2 quarters · filed 2026-02-26 | $5.72M derived: sum of 3 quarters · filed 2026-02-26 | $7.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.94M 10-Q · filed 2025-11-05 | $3.85M derived: sum of 2 quarters · filed 2025-11-05 | $5.75M 10-Q · filed 2025-11-05 | $6.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.91M 10-Q · filed 2025-08-05 | $3.82M 10-Q · filed 2025-08-05 | $4.87M derived: sum of 3 quarters · filed 2026-02-26 | $5.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.91M 10-Q · filed 2025-05-07 | $2.96M derived: sum of 2 quarters · filed 2026-02-26 | $3.90M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.00M derived: sum of 2 quarters · filed 2026-02-26 | $3.79M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $943.00K 10-Q · filed 2024-11-07 | $2.73M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |